KR102259255B1 - 뒤시엔느 근위축증의 치료에서의 항-Flt-1 항체 - Google Patents

뒤시엔느 근위축증의 치료에서의 항-Flt-1 항체 Download PDF

Info

Publication number
KR102259255B1
KR102259255B1 KR1020157021136A KR20157021136A KR102259255B1 KR 102259255 B1 KR102259255 B1 KR 102259255B1 KR 1020157021136 A KR1020157021136 A KR 1020157021136A KR 20157021136 A KR20157021136 A KR 20157021136A KR 102259255 B1 KR102259255 B1 KR 102259255B1
Authority
KR
South Korea
Prior art keywords
muscle
flt
antibody
pharmaceutical composition
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157021136A
Other languages
English (en)
Korean (ko)
Other versions
KR20150109386A (ko
Inventor
세레네 요시야
토마스 엠. 루비
아츠시 아사쿠라
데니스 키페
로렌스 차르나스
Original Assignee
샤이어 휴먼 지네틱 테라피즈 인크.
리전츠 오브 더 유니버스티 오브 미네소타
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 샤이어 휴먼 지네틱 테라피즈 인크., 리전츠 오브 더 유니버스티 오브 미네소타 filed Critical 샤이어 휴먼 지네틱 테라피즈 인크.
Publication of KR20150109386A publication Critical patent/KR20150109386A/ko
Application granted granted Critical
Publication of KR102259255B1 publication Critical patent/KR102259255B1/ko
Assigned to 다케다 야쿠힌 고교 가부시키가이샤 reassignment 다케다 야쿠힌 고교 가부시키가이샤 권리지분의 전부이전등록 Assignors: 샤이어 휴먼 지네틱 테라피즈 인크.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020157021136A 2013-01-28 2014-01-28 뒤시엔느 근위축증의 치료에서의 항-Flt-1 항체 Active KR102259255B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361757571P 2013-01-28 2013-01-28
US61/757,571 2013-01-28
PCT/US2014/013402 WO2014117160A1 (en) 2013-01-28 2014-01-28 Anti-flt-1 antibodies in treating duchenne muscular dystrophy

Publications (2)

Publication Number Publication Date
KR20150109386A KR20150109386A (ko) 2015-10-01
KR102259255B1 true KR102259255B1 (ko) 2021-05-31

Family

ID=50073518

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157021136A Active KR102259255B1 (ko) 2013-01-28 2014-01-28 뒤시엔느 근위축증의 치료에서의 항-Flt-1 항체

Country Status (14)

Country Link
US (3) US9957324B2 (https=)
EP (1) EP2948476B1 (https=)
JP (2) JP6469022B2 (https=)
KR (1) KR102259255B1 (https=)
CN (1) CN104955843B (https=)
AU (1) AU2014209012B2 (https=)
BR (1) BR112015017242B1 (https=)
CA (1) CA2898998C (https=)
EA (1) EA037501B1 (https=)
ES (1) ES2676406T3 (https=)
HK (1) HK1213918A1 (https=)
IL (1) IL238588B (https=)
MX (1) MX360153B (https=)
WO (1) WO2014117160A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230140362A (ko) 2022-03-24 2023-10-06 주식회사 케이에스비튜젠 항-Fetuin-B 항체 및 해당 항체를 유효 성분으로 포함하는 근육질환의 예방, 치료 또는 개선용 조성물

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729746B2 (en) 2013-01-28 2020-08-04 Shire Human Genetic Therapies, Inc. Recombinant placenta growth factor for treating Duchenne muscular dystrophy
CN107683143A (zh) * 2015-04-07 2018-02-09 夏尔人类遗传性治疗公司 治疗支气管肺发育不良的抗flt‑1抗体
MA41899A (fr) * 2015-04-07 2018-02-13 Shire Human Genetic Therapies Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne
CN107690335A (zh) 2015-04-07 2018-02-13 夏尔人类遗传性治疗公司 治疗支气管肺发育不良的抗flt‑1抗体
KR102019048B1 (ko) 2017-02-06 2019-09-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 근육긴장저하 치료제 스크리닝 방법
KR101886788B1 (ko) 2017-02-07 2018-08-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 뒤시엔느 골격근 위축증 치료제 스크리닝 방법
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006055809A2 (en) * 2004-11-18 2006-05-26 Imclone Systems Incorporated Antibodies against vascular endothelial growth factor receptor-1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006055809A2 (en) * 2004-11-18 2006-05-26 Imclone Systems Incorporated Antibodies against vascular endothelial growth factor receptor-1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Verma 등, Human Molecular Genetics, 2010, Vol. 19, No. 21 4145-4159*

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230140362A (ko) 2022-03-24 2023-10-06 주식회사 케이에스비튜젠 항-Fetuin-B 항체 및 해당 항체를 유효 성분으로 포함하는 근육질환의 예방, 치료 또는 개선용 조성물

Also Published As

Publication number Publication date
US20180312593A1 (en) 2018-11-01
MX360153B (es) 2018-10-24
EA201590720A8 (ru) 2018-09-28
HK1217710A1 (en) 2017-01-20
US20150361174A1 (en) 2015-12-17
IL238588A0 (en) 2015-06-30
IL238588B (en) 2020-04-30
CN104955843A (zh) 2015-09-30
CN104955843B (zh) 2019-08-13
WO2014117160A1 (en) 2014-07-31
US20210163603A1 (en) 2021-06-03
AU2014209012A1 (en) 2015-05-21
JP2019023230A (ja) 2019-02-14
HK1213918A1 (zh) 2016-07-15
CA2898998C (en) 2023-02-14
EP2948476B1 (en) 2018-06-06
EA037501B1 (ru) 2021-04-05
EP2948476A1 (en) 2015-12-02
CA2898998A1 (en) 2014-07-31
US9957324B2 (en) 2018-05-01
BR112015017242B1 (pt) 2023-11-07
JP2016511234A (ja) 2016-04-14
EA201590720A1 (ru) 2015-11-30
KR20150109386A (ko) 2015-10-01
JP6469022B2 (ja) 2019-02-13
BR112015017242A2 (https=) 2017-08-15
MX2015009690A (es) 2016-03-31
ES2676406T3 (es) 2018-07-19
AU2014209012B2 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
KR102259255B1 (ko) 뒤시엔느 근위축증의 치료에서의 항-Flt-1 항체
JP6475639B2 (ja) デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン
JP7456989B2 (ja) デュシェンヌ型筋ジストロフィーの治療における抗ｆｌｔ－１抗体
JP2019509735A (ja) デュシェンヌ型筋ジストロフィー治療における組換えフォリスタチン−Ｆｃ融合タンパク質及び使用
JP2020519291A (ja) 組み換えフォリスタチン−ｆｃ融合タンパク質およびデュシェンヌ型筋ジストロフィーの治療における使用
HK1217710B (en) Anti-flt-1 antibodies in treating duchenne muscular dystrophy
BR122024023570A2 (pt) Polinucleotídeo que codifica um anticorpo anti-flt-1 ou seu fragmento de ligação ao antígeno, composição farmacêutica, usos relacionados, vetor de expressão, célula isolada e anticorpos anti-flt-1 ou seu fragmento de ligação ao antígeno
BR112017021414B1 (pt) Anticorpos anti-flt-1 e composição farmacêutica compreendendo os referidos anticorpos

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150804

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190103

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200615

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210310

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210526

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210526

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240424

Start annual number: 4

End annual number: 4